GlassScriptPhysician profile
Manali D Shah
NPI 1871150151
$22,073.91
in general payments reported to CMS, 2019-2025
9 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $9,537 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $1,647 · Travel and Lodging: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,242.00 |
| Food and Beverage | $1,647.45 |
| Travel and Lodging | $1,184.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,162.00 | 2024-2025 | |
| Genentech USA, INC. | $6,431.21 | 2024-2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $3,019.00 | 2025 | |
| Merck Healthcare Kgaa | $2,923.92 | 2025 | |
| Emd Serono, INC. | $1,944.02 | 2024 | |
| Genentech, INC. | $190.21 | 2024 | |
| Biogen, INC. | $188.72 | 2024 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $166.83 | 2024 | |
| Alexion Pharmaceuticals, INC. | $48.00 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manali Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.